Assessment of adverse effects in clinical studies of antipsychotic medication: Survey of methods used

British Journal of Psychiatry

Volumn 197, Issue 1, 2010, Pages 67-72

  Pope, Alison ^a   Adams, Clive ^b   Paton, Carol ^a   Weaver, Tim ^a   Barnes, Thomas R E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADVERSE DRUG REACTION; ARTICLE; AVERSIVE BEHAVIOR; CLINICAL RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METABOLIC DISORDER; METHODOLOGY; RATING SCALE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; DYSKINESIA, DRUG-INDUCED; HUMANS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; WEIGHT GAIN;

EID: 77954581120     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.109.070961     Document Type: Article

References (32)

1. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079-87.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
3. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-63.
4. National Institute for Health and Clinical Excellence. Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). National Clinical Practice Guideline 82. NICE, 2009.
5. Jordan S, Knight J, Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. Int Nurs Rev 2004; 51: 208-21.
6. Byerly MJ, Nakonezny PA, Fisher R, Magouirk B, Rush AJ. An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophr Res 2006; 81: 311-6.
7. Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007; 22: 238-43.
8. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage 1999; 18: 427-37.
9. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials. An evaluation of 7 medical areas. JAMA 2001; 285: 437-43.
10. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol 2001; 1: 3.
11. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JPA. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry 2004; 161: 1692-7.
12. Adams CE, Coutinho ESF, Davis J, Duggan L, Leucht S, Li C, et al. Cochrane Schizophrenia Group. Schizophr Bull 2008; 34: 259-65.
13. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary, issue 52. BMJ Books/Pharmaceutical Press, 2006.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
15. Fakhoury WKH, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom national mental health helpline. Int Clin Psychopharmacol 2001; 16: 153-62. (Pubitemid 32402360)
16. Finn SE, Bailey JM, Schultz RT, Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990; 20: 843-8.
17. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-7.
18. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212: 11-9.
19. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6.
20. Guy W (ed). ECDEU Assessment Manual for Psychopharmacology: 534-7. Publication ADM 76-338. US Department of Health, Education, and Welfare, 1976.
21. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177-83. (Pubitemid 13132147)
22. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998; 317: 1181-4.
23. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 (suppl 7): s22-31.
24. Marder SR, Schooler SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-49.
25. Rosenberg KP, Bleiberg KL, Koscis J, Gross C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003; 29: 289-96.
26. Ozbilen M, Adams CE. Systematic overview of Cochrane Reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol 2009; 29: 141-6.
27. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic treated patients. Acta Psychiatr Scand 1987; 334: 1-100.
28. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995; 166: 650-3.
29. Hayashi K, Walker AM. Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Control Clin Trials 1996; 17: 99-110.
30. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 657-62.
31. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-94.
32. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007; 8: 38.